



INTEGRATIVE THERAPEUTICS INC.*
 NF Formulas + PhytoPharmica
 Tyler Encapsulations + Vitaline Formulas

9755 SW Commerce Circle, Suite B2
 Wilsonville, OR 97070
 P: 503.582.8386 + F: 503.582.0467

ENZYMATIC THERAPY*
 &
PHYTOPHARMICA*

825 Challenger Drive, Green Bay, WI 54311-8328
 P: 920.469.1313 + F: 888.570.6460 (Enzymatic)
 P: 920.469.9099 + F: 920.469.4418 (Phyto)

ENZYMATIC THERAPY
 INCORPORATED

*What **Better** feels like.™*

August 24, 2004

Office of Nutritional Products, Labeling &
 Dietary Supplements, HFS 810
 Center for Food Safety and Applied Nutrition
 Food and Drug Administration
 5100 Paint Branch Parkway
 College Park, MD 20740




RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>PRODUCT NAME</u>	<u>STATEMENTS</u>	<u>INGREDIENT(S) TO WHICH THE CLAIM REFERS</u>
Eskimo-3®	EFA's are a chief component of cell membranes that regulate the intake of necessary nutrients and output of toxins from metabolic functions within the cell.*	Omega-3 fatty acids including 210-270 mg EPA (eicosapentaenoic acid) and 125-175 mg DHA (docosahexaenoic acid)

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
 Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 8/24/04

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,


 Michael P. Devereux
 Chief Financial Officer

97S 0162

LET 14593



INTEGRATIVE THERAPEUTICS INC.™
 NF Formulas + PhytoPharmica
 Tyler Encapsulations + Vitaline Formulas

ENZYMATIC THERAPY®
 &
PHYTOPHARMICA®

ENZYMATIC THERAPY
 INCORPORATED

9755 SW Commerce Circle, Suite B2
 Wilsonville, OR 97070
 P: 503.582.8386 + F: 503.582.0467

825 Challenger Drive, Green Bay, WI 54311-8328
 P: 920.469.1313 + F: 888.570.6460 (Enzymatic)
 P: 920.469.9099 + F: 920.469.4418 (Phyto)

What **Better** feels like.™

August 24, 2004

Office of Nutritional Products, Labeling &
 Dietary Supplements, HFS 810
 Center for Food Safety and Applied Nutrition
 Food and Drug Administration
 5100 Paint Branch Parkway
 College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>PRODUCT NAME</u>	<u>STATEMENTS</u>	<u>INGREDIENT(S) TO WHICH THE CLAIM REFERS</u>
Eskimo-3®	New power-packed healthy aging protocol promotes natural immune defense and provides support against the natural signs of aging.* Even more, these clinically-validated products support healthy neurological, cardiovascular and immune system function.*	Omega-3 fatty acids including 210-270 mg EPA (eicosapentaenoic acid) and 125-175 mg DHA (docosahexaenoic acid)

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 
 Robert C. Doster
 Title: Senior Vice President of Scientific Affairs
 Date: 8/24/04

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

 Michael P. Devereux
 Chief Financial Officer